Extended survival outcomes are becoming increasingly common after a diagnosis of multiple myeloma. What are some of the therapies responsible for these advances, and how far are we extending survival? Further, we’re learning that certain combination therapies are more effective for certain patients. How can we determine which patients are viable candidates for a specific treatment regimen? Dr. James Berenson, founding president and chief executive officer of the Institute for Myeloma and Bone Cancer Research in West Hollywood, Calif., probes these issues and more with host Dr. Mark Nolan Hill.
ReachMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Multiple Myeloma: Current Treatment Modalities
Share this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Presenters
Recommended
Details
Presenters
Comments
Recommended
Overview
Extended survival outcomes are becoming increasingly common after a diagnosis of multiple myeloma. What are some of the therapies responsible for these advances, and how far are we extending survival? Further, we’re learning that certain combination therapies are more effective for certain patients. How can we determine which patients are viable candidates for a specific treatment regimen? Dr. James Berenson, founding president and chief executive officer of the Institute for Myeloma and Bone Cancer Research in West Hollywood, Calif., probes these issues and more with host Dr. Mark Nolan Hill.
Presenters
Facebook Comments